Literature DB >> 18846035

5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles.

F Afzal1, K W Andressen, H K Mørk, J M Aronsen, I Sjaastad, C P Dahl, T Skomedal, F O Levy, J-B Osnes, E Qvigstad.   

Abstract

BACKGROUND AND
PURPOSE: The left ventricle in failing hearts becomes sensitive to 5-HT parallelled by appearance of functional G(s)-coupled 5-HT(4) receptors. Here, we have explored the regulatory functions of phosphodiesterases in the 5-HT(4) receptor-mediated functional effects in ventricular muscle from failing rat and human heart. EXPERIMENTAL APPROACH: Extensive myocardial infarctions were induced by coronary artery ligation in Wistar rats. Contractility was measured in left ventricular papillary muscles of rat, 6 weeks after surgery and in left ventricular trabeculae from explanted human hearts. cAMP was quantified by RIA. KEY
RESULTS: In papillary muscles from postinfarction rat hearts, 5-HT(4) stimulation exerted positive inotropic and lusitropic effects and increased cAMP. The inotropic effect was increased by non-selective PDE inhibition (IBMX, 10 microM) and selective inhibition of PDE3 (cilostamide, 1 microM), but not of PDE2 (EHNA, 10 microM) or PDE4 (rolipram, 10 microM). Combined PDE3 and PDE4 inhibition enhanced inotropic responses beyond the effect of PDE3 inhibition alone, increased the sensitivity to 5-HT, and also revealed an inotropic response in control (sham-operated) rat ventricle. Lusitropic effects were increased only during combined PDE inhibition. In failing human ventricle, the 5-HT(4) receptor-mediated positive inotropic response was regulated by PDEs in a manner similar to that in postinfarction rat hearts. CONCLUSIONS AND IMPLICATIONS: 5-HT(4) receptor-mediated positive inotropic responses in failing rat ventricle were cAMP-dependent. PDE3 was the main PDE regulating this response and involvement of PDE4 was disclosed by concomitant inhibition of PDE3 in both postinfarction rat and failing human hearts. 5-HT, PDE3 and PDE4 may have pathophysiological functions in heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18846035      PMCID: PMC2597261          DOI: 10.1038/bjp.2008.339

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  46 in total

1.  A uniform extracellular stimulus triggers distinct cAMP signals in different compartments of a simple cell.

Authors:  T C Rich; K A Fagan; T E Tse; J Schaack; D M Cooper; J W Karpen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

2.  Cyclic nucleotide research -- still expanding after half a century.

Authors:  Joseph A Beavo; Laurence L Brunton
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

3.  Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase a.

Authors:  C L Antos; N Frey; S O Marx; S Reiken; M Gaburjakova; J A Richardson; A R Marks; E N Olson
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

4.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.

Authors:  Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade
Journal:  JAMA       Date:  2002-03-27       Impact factor: 56.272

5.  Positive inotropic effects of phenylephrine in the isolated rabbit papillary muscle mediated both by alpha- and beta-adrenoceptors.

Authors:  H J Schümann; M Endo; J Wagner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

6.  Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure.

Authors:  Koki Takahashi; Tomohiro Osanai; Takao Nakano; Makoto Wakui; Ken Okumura
Journal:  Heart Vessels       Date:  2002-09       Impact factor: 2.037

7.  Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei.

Authors:  C Lugnier; T Keravis; A Le Bec; O Pauvert; S Proteau; E Rousseau
Journal:  Biochim Biophys Acta       Date:  1999-11-16

8.  Phosphodiesterase-4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac beta(1)-adrenoceptors.

Authors:  A Galindo-Tovar; A J Kaumann
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

9.  Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes.

Authors:  Manuela Zaccolo; Tullio Pozzan
Journal:  Science       Date:  2002-03-01       Impact factor: 47.728

10.  beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.

Authors:  George S Baillie; Arvind Sood; Ian McPhee; Irene Gall; Stephen J Perry; Robert J Lefkowitz; Miles D Houslay
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

View more
  14 in total

1.  Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium.

Authors:  Sabine Weninger; Joris H De Maeyer; Romain A Lefebvre
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-03       Impact factor: 3.000

2.  The effects of serotonin on the electrophysiological properties of atrioventricular node during an experimental atrial fibrillation.

Authors:  Shima Changizi; Vahid Khori; Ali Mohammad Alizadeh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-22       Impact factor: 3.000

3.  Differential regulation of β2 -adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle.

Authors:  Faraz Afzal; Jan Magnus Aronsen; Lise Román Moltzau; Ivar Sjaastad; Finn Olav Levy; Tor Skomedal; Jan-Bjørn Osnes; Eirik Qvigstad
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

5.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium.

Authors:  Lise Román Moltzau; Silja Meier; Jan Magnus Aronsen; Faraz Afzal; Ivar Sjaastad; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Eirik Qvigstad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-01-15       Impact factor: 3.000

7.  Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility.

Authors:  Finn Olav Levy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-07       Impact factor: 3.000

8.  The cardiac ventricular 5-HT4 receptor is functional in late foetal development and is reactivated in heart failure.

Authors:  Trond Brattelid; Eirik Qvigstad; Lise R Moltzau; Silje V S Bekkevold; Dagny L Sandnes; Jon Arne K Birkeland; Tor Skomedal; Jan-Bjørn Osnes; Ivar Sjaastad; Finn Olav Levy
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

9.  Phosphodiesterases 2, 3 and 4 can decrease cardiac effects of H2-histamine-receptor activation in isolated atria of transgenic mice.

Authors:  Joachim Neumann; Rafaela Voss; Ulrich Laufs; Christian Werner; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-02-12       Impact factor: 3.000

Review 10.  Spatial control of the βAR system in heart failure: the transverse tubule and beyond.

Authors:  Julia Gorelik; Peter T Wright; Alexander R Lyon; Sian E Harding
Journal:  Cardiovasc Res       Date:  2013-01-23       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.